Shan Lin is Professor of Clinical Ophthalmology at the University of California, San Francisco, and Director of the Glaucoma Service at UCSF and the Zuckerberg San Francisco General Hospital. His research interests include: 1) angle closure glaucoma; 2) glaucoma among Asians; 3) cyclodestructive procedures, and 4) the role of cataract surgery in glaucoma treatment. His leadership positions include Chair of the American Glaucoma Society’s Patient Care Committee, past Chair of the Glaucoma Section of the Ophthalmic Technology Assessment Committee of the American Academy of Ophthalmology, past Chair of the American Glaucoma Society’s Document Review Subcommittee, and past President, Vice President and Program Chair of the Pacific Coast Oto-Ophthalmological Society (PCOOS). His past honors include the Heed Fellowship Award, the American Glaucoma Society and The Glaucoma Foundation’s Clinician-Scientist Awards, and the Mid-Career Award by the AGS. He has also been funded as a Principal Investigator by the National Institute of Health, including as a PI for the OHTS study. In addition, Dr. Lin has been the PI at UCSF for many industry-sponsored trials including the Memantine Glaucoma Trial by Allergan and the Ranibizumab-Adjunctive Study for Ahmed Valve Surgery by Genentech. He has been selected annually for “Best Doctors” in the U.S. since 2009. He has received the AAO’s Achievement Award, Secretariat Award, and Senior Achievement Award. Dr. Lin has given numerous named lectures and talks nationally and internationally.